<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019461</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066216</org_study_id>
    <secondary_id>NCI-98-C-0012</secondary_id>
    <secondary_id>NCI-T97-0112</secondary_id>
    <nct_id>NCT00019461</nct_id>
    <nct_alias>NCT00001682</nct_alias>
  </id_info>
  <brief_title>Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Trial of Orally Administered CAI for Patients With Persistent or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in treating&#xD;
      patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary&#xD;
      peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical outcome in patients with ovarian epithelial, fallopian tube, or&#xD;
           primary peritoneal cancer treated with carboxyamidotriazole.&#xD;
&#xD;
      OUTLINE: Patients receive oral carboxyamidotriazole daily beginning on day 1. Treatment&#xD;
      continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-40 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1998</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboxyamidotriazole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed refractory or recurrent ovarian epithelial, fallopian tube,&#xD;
             or primary peritoneal cancer&#xD;
&#xD;
          -  Measurable disease by physical exam, radiography, peritoneoscopy, or laparoscopy&#xD;
&#xD;
               -  No more than 4 weeks since prior peritoneoscopy&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL AND/OR&#xD;
&#xD;
          -  Hematocrit at least 27%&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT/SGPT no greater than 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of symptomatic cardiac dysrhythmias requiring medication&#xD;
&#xD;
          -  At least 6 months since prior myocardial infarction&#xD;
&#xD;
          -  No unstable or newly diagnosed angina&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No obstructive lung disease requiring oxygen therapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Must be able to take oral medication&#xD;
&#xD;
          -  No concurrent medical condition (e.g., impending bowel obstruction)&#xD;
&#xD;
          -  No grade 2 or greater residual peripheral neuropathy&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other prior or concurrent invasive malignancy within the past 5 years&#xD;
&#xD;
          -  No history of acute visual loss other than that associated with retinal detachment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior cytokine therapy&#xD;
&#xD;
          -  No concurrent cytokine therapy to maintain WBC count&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carboplatin, or&#xD;
             mitomycin)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior hormonal therapy&#xD;
&#xD;
          -  No concurrent corticosteroids at doses greater than physiological replacement doses&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No more than 3 prior treatment regimens&#xD;
&#xD;
          -  At least 1 week since prior systemic antibiotics for infection&#xD;
&#xD;
          -  No chronic antifungal treatment with antimycotic imidazoles&#xD;
&#xD;
          -  No concurrent alternative therapies&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahrukh Hussain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai S, Steinberg SM, Raggio M, Oliver VK, Figg WD, Kohn EC. Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer. J Clin Oncol. 2003 Dec 1;21(23):4356-63.</citation>
    <PMID>14645425</PMID>
  </results_reference>
  <verification_date>June 2003</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboxyamido-triazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

